Form 4: Pulmonx Director Georgia Melenikiotou Receives RSU Grant

Director Georgia Melenikiotou was granted 40,000 restricted stock units in Pulmonx Corporation.

Summary

• Director Georgia Melenikiotou acquired 40,000 restricted stock units (RSUs) of Pulmonx Corporation common stock.
• The transaction occurred on June 5, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership of common stock is 139,714 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

• The RSU grant aligns the director's interests with those of shareholders through equity-based compensation.

Negatives

• None noted.

Risks

• The value of the equity grant is subject to market volatility and the future performance of Pulmonx Corporation stock.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date (June 5, 2027) or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded medical technology companies.
• The vesting schedule of one year or the next annual meeting is a common industry practice for director equity awards.

Stakeholder Impact

• Shareholders may view the equity grant as a standard alignment of director incentives with company performance.

Next Steps

• Vesting of the 40,000 RSUs on June 5, 2027, or the date of the 2027 annual meeting of stockholders.

Key Dates

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Director Compensation, Restricted Stock Units